Colorado Posterior Cortical Atrophy Support Webinar
Review of the recent FDA approval of Aduhelm (aducanumab)
for Alzheimer’s disease
See Below For Registration
The Food and Drug Administration (FDA) recently approved Aduhelm (aducanumab) for Alzheimer’s disease through their accelerated approval pathway. Dr. Pelak will review the Posterior Cortical Atrophy syndrome, the basic biology of Alzheimer’s disease, the mechanism of action of Aduhelm, and controversy surrounding the FDA approval. All are invited, with the webinar designed for people with posterior cortical atrophy, their care partners. friends and family, and all with an interest in learning more about Alzheimer’s disease and Aduhelm.
Sponsored by generous donors of the Brain and Vision Fund at the University of Colorado